Results 61 to 70 of about 53,199 (230)

Chalazia development in multiple myeloma: a new complication associated with bortezomib therapy

Hematology Reports, 2015
Multiple myeloma (MM) is a neoplasm of plasma cells within the bone marrow. A major impact on improving survival in MM has been the use of the boronic acid-derived proteasome inhibitor bortezomib, a first-in-class selective inhibitor of the 26S ...
Charles Yun, Nikhil Mukhi, Valerie Kremer, Roman Shinder, Vaibhav Verma, Olcay Batuman   +5 more
doaj   +1 more source

Stereochemical Control in the Matteson Reaction

Chemistry – A European Journal, EarlyView.
The Matteson homologation is a highly versatile method for the stereoselective insertion of carbenoids into boronic esters. Through iterative application of the process, complex chiral molecules can be synthesized. The stereoselectivity of the reaction is determined by a chiral diol incorporated in the boronic ester.
Hae Mo Lee, Christoph Hirschhäuser
wiley   +1 more source

N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair

Frontiers in Cell and Developmental Biology
Studies have shown that bortezomib resistance in multiple myeloma (MM) is mediated by the abnormalities of various molecules and microenvironments. Exploring these resistance mechanisms will improve the therapeutic efficacy of bortezomib.
Siyi Jiang, Lili Gao, Jian Li, Fangrong Zhang, Yanan Zhang, Jing Liu   +5 more
doaj   +1 more source

Prognostic Significance of Peripheral Blood Neutrophil‐To‐Lymphocyte Ratio (NLR), Monocyte‐To‐Lymphocyte Ratio (MLR), and Platelet‐To‐Lymphocyte Ratio (PLR) in Patients With Multiple Myeloma: A Retrospective Cohort Study

Journal of Clinical Laboratory Analysis, EarlyView.
This graphical abstract illustrates the prognostic significance of systemic inflammatory markers in Multiple Myeloma (MM). The left panel depicts the immunosuppressive tumor microenvironment, where abundant neutrophils and M2 macrophages promote MM cell survival while lymphocytes are depleted.
Lihong Zhang, Bing Ma, Jingyu Zhang
wiley   +1 more source

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Haematologica, 2012
The phase III MMY-3021 study compared safety and efficacy of subcutaneous versus intravenous administration of the proteasome inhibitor bortezomib in patients with relapsed myeloma.
Bertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Helgi van de Velde, Huaibao Feng, Andrew Cakana, William Deraedt, Philippe Moreau   +9 more
doaj   +1 more source

Laboratory Identification of Pseudohypercalcemia Induced by Hyperglobulinemia in Multiple Myeloma: A Case Report

Journal of Clinical Laboratory Analysis, EarlyView.
Pseudohypercalcemia induced by calcium‐binding monoclonal immunoglobulin in multiple myeloma is verified via laboratory assays and validated by therapeutic response. ABSTRACT Background Pseudohypercalcemia is easily misdiagnosed in clinical practice, potentially leading to unnecessary interventions.
Anjiang Zhao, Fan Zhong, Yankui Liu, Guixing Li   +3 more
wiley   +1 more source

Multiomics Insights Into AL Amyloidosis

Medicine Bulletin, EarlyView.
ABSTRACT Light chain amyloidosis is a systemic or localized protein conformational disorder triggered by misfolded immunoglobulin light chains, leading to amyloid fibril deposition. The disease is characterized by multiorgan involvement and delayed diagnosis, contributing to poor prognosis and high mortality rates.
Zixuan Zhang, Ziru Huang, Haoxiang Tang, Xianrun Pan, Rong Wang, Dingding Zhang, Jian Huang   +6 more
wiley   +1 more source

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib

Parasites & Vectors, 2009
The proteasome inhibitor and anti-cancer drug bortezomib was tested for in vitro activity against bloodstream forms of Trypanosoma brucei. The concentrations of bortezomib required to reduce the growth rate by 50% and to kill all trypanosomes were 3.3 nM
Wang Xia, Steverding Dietmar
doaj   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

Experimental study on forskolin combined with bortezomib inducing apoptosis in bortezomibresistant multiple myeloma cells

Zhongguo aizheng zazhi, 2016
Background and purpose: Although bortezomib has become one of the major therapeutic agents against newly diagnosed or relapsed multiple myeloma (MM), there are some patients who become resistant to bortezomib and then relapse, emerging as a major ...
王莹莹, 钟　瑶, 俞夜花
doaj